Trials
1 active
2 in total · 1 in the EU
What this is
- How it works
- How it works isn't classified yet
- Tested for
- Adult Acute Myeloid Leukemia
- Main trialPhase 3
- “This is a multi-center, randomized, double-blinded, placebo controlled trial.”In the company’s words, NCT05429632 on ClinicalTrials.gov
- Other names
- KRP-203
Other drugs for Adult Acute Myeloid Leukemia
- Pivekimab SunirineAbbVie · Phase 2/3
- QTX-2101Quetzal Therapeutics · Phase 3
- ZiftomenibKura Oncology, Inc. · Phase 3
- QuizartinibDaiichi Sankyo · Phase 3
- ATOSDK Therapeutics, Inc. · Phase 3
- IvosidenibServier Bio-Innovation LLC · Phase 3
Coming up1
- May 2027Phase 3 trial completes · ClinicalTrials.gov
Changes1
Last 90 days- 13 NovNew trial: none to Phase 1 · ClinicalTrials.gov NCT07937046
Trials2
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Recruiting | May 2027 | Mocravimod as Adjunctive and Maintenance Treatment in AML Patients Undergoing Allo-HCT | |
| Phase 1Completed | 16 May 2011 | Single and Multiple Ascending Dose Study of KRP-203 in Healthy Japanese Adults |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026